Assessing IL-17 levels in patients with spondyloarthritis
Feasibility of an Il-17a Assay and Impact on Therapeutic Response in Patients With Active Axial Spondyloarthritis
This study is testing if measuring IL-17 levels in patients with active spondyloarthritis can help doctors choose the best biological treatment after other medications haven't worked.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Nice) |
| Trial ID | NCT05592574 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the feasibility of measuring IL-17 cytokine levels in patients with active spondyloarthritis (axSpA) who require biological treatment after failing at least two non-steroidal anti-inflammatory drugs (NSAIDs). By stimulating immune cells and analyzing cytokine responses, the study seeks to develop a tool that could assist clinicians in selecting the most appropriate biologic therapy for these patients. The study focuses on patients meeting the ASAS criteria for spondyloarthritis and aims to address the lack of validated biomarkers in this area.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with active spondyloarthritis who have not responded to at least two NSAIDs and meet the ASAS criteria.
Not a fit: Patients with predominant axial manifestations or those who have previously received biological treatments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a valuable tool for clinicians to make more informed decisions regarding biologic treatments for patients with spondyloarthritis.
How similar studies have performed: While there have been head-to-head studies comparing biologics in related conditions, this specific approach to cytokine measurement in spondyloarthritis is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Patients with spondyloarthritis meeting the ASAS criteria * Patients who were to benefit from the implementation of a biological treatment after failure of at least two NSAIDs. * Patients having an active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) higher than four, Exclusion criteria * No predominant axial manifestation, * Having received a previous biological treatment * Patients presenting contraindication to the implementation of these treatments.
Where this trial is running
Nice
- CHU de NICE — Nice, France (Recruiting)
Study contacts
- Study coordinator: Christian ROUX
- Email: roux.c2@chu-nice.fr
- Phone: +33492035491
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.